Telomir Pharmaceuticals (NASDAQ:TELO) Trading Up 3.8% – Still a Buy?

Shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) were up 3.8% during mid-day trading on Monday . The company traded as high as $4.42 and last traded at $4.38. Approximately 41,805 shares traded hands during mid-day trading, a decline of 47% from the average daily volume of 78,525 shares. The stock had previously closed at $4.22.

Telomir Pharmaceuticals Stock Up 3.8 %

The business has a 50 day moving average of $5.31 and a 200-day moving average of $5.18.

Telomir Pharmaceuticals (NASDAQ:TELO) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.05) earnings per share for the quarter.

Institutional Investors Weigh In On Telomir Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Suncoast Equity Management boosted its holdings in shares of Telomir Pharmaceuticals by 109.9% during the third quarter. Suncoast Equity Management now owns 51,194 shares of the company’s stock worth $329,000 after purchasing an additional 26,803 shares during the last quarter. Beaird Harris Wealth Management LLC boosted its holdings in shares of Telomir Pharmaceuticals by 212.9% during the second quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company’s stock worth $70,000 after purchasing an additional 9,950 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Telomir Pharmaceuticals during the second quarter worth $241,000.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.